Navigation Links
Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy
Date:10/1/2007

- Data from Positive VENT Trial Presented at ERS 17th Annual Congress -

REDWOOD CITY, Calif., Oct. 1 /PRNewswire/ -- Emphasys Medical Inc. today announced the submission of a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) requesting regulatory approval to market the Emphasys endobronchial valve, the Zephyr(R) EBV, in the United States. The Zephyr EBV is a minimally invasive and potentially reversible treatment option intended to help patients with emphysema breathe easier.

The PMA submission was based on data from the company's pivotal trial, the Endobronchial Valve for Emphysema PalliatioN Trial (VENT). VENT was a randomized, multi-center trial enrolling 321 patients with severe heterogeneous emphysema. This trial was designed based on input from a panel of expert clinicians convened by the FDA in February 2003 to help establish the appropriate clinical endpoints for medical device treatments of emphysema. The VENT study's primary efficacy endpoints were improvement in lung function as measured by forced expiratory volume in one second (change in FEV1) and exercise tolerance as measured by a six minute walk test (6MWT) both at six months. The primary safety endpoint was a composite of major complications at six months.

Data from VENT was recently presented at the European Respiratory Society (ERS) 17th Annual Congress. VENT met both its primary efficacy endpoints showing statistically significant improvements in lung function (p=0.0047) and exercise tolerance (p=0.0073). VENT also showed the Zephyr EBV to have a favorable safety profile in terms of major complications between the treatment and control groups. At the six-month follow-up, protocol-defined major complications occurred in 5.9% of treated patients compared to 1.0% of control patients. The difference did not reach statistical significance. Investigators also reported on select patient subsets. In patients defined as having physiologically isol
'/>"/>

SOURCE Emphasys Medical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... How best to treat and recover from ... medicine. While diagnostic hip injections are commonly performed for ... research presented today at the American Orthopaedic Society for ... pain relief from this diagnostic injection may not predict ... study looked to assess if the amount of pain ...
(Date:3/28/2015)... OR (PRWEB) March 28, 2015 Lately ... the media regarding recent changes and proposals around the ... , current and former collegiate student-athletes across a spectrum ... and reflect on common challenges. The special panel consists ... country in sports ranging from football, track and field, ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 ARDX will sponsor ... from 12pm -3pm at the Chesapeake Conference Center in Chesapeake, ... sponsoring an empowering event for women in the Hampton Roads ... the Stories of Women’s Lives. Women grow stronger through ... each other. This year the WWC™ theme is T-talk ...
(Date:3/27/2015)... Long Island, NY (PRWEB) March 27, 2015 ... objective, cancer-focused training and business criteria for the spa ... and services to clients who have experienced or are ... of the global Spafinder Wellness 365® Network, will be ... Spafinder.com and recognized as a provider of safe, therapeutic ...
(Date:3/27/2015)... Mo (PRWEB) March 27, 2015 ... for patients undergoing percutaneous coronary intervention (PCI), resulting ... have observed a “risk-treatment paradox,” in which the ... from treatment are treated less often with bleeding ... at Saint Luke’s Mid America Heart Institute asked ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3
... ... don,t need the pretty bottles or sweet aroma of fragrant lotions and cleansers-men ... tailored specifically to a man,s needs without added synthetic ingredients that may be ... uses the purity of nature to enhance the skin,s surface and makes a ...
... ... Drive in Beverly Hills to Main Street in small towns across America. The medical community ... growing epidemic. , ... PA (PRWEB) June 1, 2010 -- Nearly 7 million Americans are abusing prescription drugs – ...
... ... Harmful Bacteria, Including MRSA. Jan-Pro, Global Leader in Commercial Cleaning, Once Again Leads the ... Offer Powerful New Solution in the control of infectious microorganisms - EnviroShield Disinfectant Technology ... (PRWEB) June ...
... ... of a novel combination of two FDA Approved topical medications. This triple blind controlled ... ... Oscar Klein M.D. today announced the results of a triple blind hair loss research study ...
... ... a brand new buy back plan. , ... (PRWEB) – CosmeticLaserWorld.com ( www.cosmeticlaserworld.com ), a market leader in ... should purchase equipment from the reseller. Under an Investment Protection Plan, the company will ...
... - Shionogi Pharma, Inc., a U.S.-based group company of ... results of two pivotal studies of the investigational new ... for the treatment of primary premature ejaculation (PE). These ... (AUA) Annual Meeting in San Francisco. Evaluating a ...
Cached Medicine News:Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 2Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 3Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 4Health News:Medical Community Responds to Prescription Drug Abuse 2Health News:Medical Community Responds to Prescription Drug Abuse 3Health News:JAN-PRO Launches Exclusive “EnviroShield™” Disinfecting System - Kills Harmful Bacteria, Including MRSA 2Health News:JAN-PRO Launches Exclusive “EnviroShield™” Disinfecting System - Kills Harmful Bacteria, Including MRSA 3Health News:Hair Loss Research Study Reveals Important Breakthrough in the Treatment of Male Pattern Baldness 2Health News:Hair Loss Research Study Reveals Important Breakthrough in the Treatment of Male Pattern Baldness 3Health News:CosmeticLaserWorld.com Gives Buyers Peace of Mind Through Industry-Leading Investment Protection Plan 2Health News:Pivotal data for the investigational treatment PSD502 for primary premature ejaculation 2Health News:Pivotal data for the investigational treatment PSD502 for primary premature ejaculation 3
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
(Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
(Date:3/27/2015)... 27, 2015  Johnson & Johnson (NYSE: JNJ ) ... (Eastern Time) on Thursday, April 23, 2015, from the State ... Investors and other interested parties may access the live ... at www.jnj.com and clicking on the webcast icon. ... be made available a few hours after the live meeting ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... Inc. (Nasdaq: MYL ) CEO Heather Bresch today ... Committee at a hearing hosted by the subcommittee on Health ... Fees and Further Examination of Drug Shortages." In ... of mind in knowing that every prescription, brand or generic, ...
... Mass., Feb. 9, 2012 Syndax Pharmaceuticals, ... that scientists at Roswell Park Cancer Institute have ... inhibitor of class I histone deacetylases, has novel ... of cancer immunotherapies in models of renal and ...
Cached Medicine Technology:Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 2Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 3Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 4Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models 2Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models 3
... control is designed for monitoring human urine ... routine and stat testing and meets CLIA ... are included for most frequently tested analytes. ... chemistry analyzers including: Aeroset, AU Series, Cobas, ...
... control validates urine dipstick readings by applying ... a plastic dropper tip designed for easy ... is the addition of creatinine and microalbumin. ... qualitative results for hCG for early pregnancy ...
... quanTtest human protein standards are available in ... and 200 mg/dL and are packaged in ... ready-to-use, requiring no reconstitution or dilution and ... purified human albumin and human globulin at ...
... is a completely new concept ... use of optic technology for ... applying touch-less vibration system (Patent ... ergonomic user friendly, novel design ...
Medicine Products: